Anatara Lifesciences Ltd (ASX:ANR) present their report on the consolidated entity consisting of Anatara Lifesciences Ltd and the entities it controlled at the end of, or during, the half-year ended 31 December 2019.
Anatara Lifesciences Ltd (ASX:ANR) CEO Steven Lydeamore was recently interviewed by Stockhead, for its "90 Seconds With" interview series. Steve provided an overview of the Company's key milestones for the next 12 months.
Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, releases its quarterly cashflow report and review of operational activities for the period ending 31 December 2019 (Q2 FY20).
Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide a summary of the preclinical studies conducted to date for its Gastrointestinal ReProgramming (GaRP) dietary supplement as it targets commencement of a human clinical trial in 2Q 2020.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st December 2019. The Company's cash plus term deposits at the end of the quarter stood at $4.30m
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, has come to a mutual agreement with Japan-based manufacturer AGC Inc to terminate their exclusive manufacturing licence and joint venture agreement.
Anatara Lifesciences (ASX:ANR) is pleased to provide an update on the protocol for its clinical trial in irritable bowel syndrome (IBS) for its GaRP dietary supplement.
Banking & Finance
- Pyx Resources Limited (NSX:PYX) Investor Presentation
- Ellis Martin Report: EMX Royalty Corp (NYSE:EMX) (CVE:EMX) Makes Strategic Investment in Ensero Solutions
- Nova Minerals Limited (ASX:NVA) Interview with Christopher Gerteisen, Director and General Manager
Oil Gas & Energy
- Genex Power Ltd (ASX:GNX) Half Year Results Announcement
- Central Petroleum Limited (ASX:CTP) Half Year Results - Reports $3.2M Maiden Net Profit
- ReconAfrica (CVE:RECO) (OTCMKTS:LGDOF) Acquires Drill Rig for the Company's Kavango Basin, Namibia Program